Search

Displaying results 7271 - 7280 of 8696 in total
  1. Drug

    RP-A501

    go.drugbank.com/drugs/DB17647
    Investigational

    It is being investigated for Danon disease.[L45934]

  2. Drug

    Actinium Ac 225 Vipivotide tetraxetan

    go.drugbank.com/drugs/DB23637
    Investigational

    Actinium Ac 225 Vipivotide Tetraxetan is under investigation in clinical trial NCT07150715 (Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for

  3. Drug

    Dexpramipexole

    go.drugbank.com/drugs/DB15130
    Investigational

    Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for

  4. Drug

    Gossypol

    go.drugbank.com/drugs/DB13044
    Investigational

    Gossypol has been used in trials studying the treatment of Non-small Cell Lung Cancer.

    Categories: Hormonal Contraceptives for Systemic Use
  5. Drug

    Fenpiprane

    go.drugbank.com/drugs/DB13439
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  6. Drug

    Tilorone

    go.drugbank.com/drugs/DB17965
    Experimental

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  7. Drug

    Sovleplenib

    go.drugbank.com/drugs/DB17557
    Investigational

    Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk).

  8. Drug

    Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-

    go.drugbank.com/drugs/DB16204
    Investigational

    Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for

  9. Drug

    Osoresnontrine

    go.drugbank.com/drugs/DB16274
    Investigational

    Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks

  10. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation